CD8A and neoplasm: In concordance with improved vasculature normalization and alleviated hypoxia, the combination therapy between MD5-1 and sunitinib enhances the number of activated tumor-infiltrating CD8+ T cells, suggesting that targeting blood vessels with anti-angiogenic therapy leads to potential benefits for immunotherapy mediated by CD8+ T cells and APCs (Tsukita et al., 2018).